Short answer
Astrana Health, Inc. (ASTH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
Astrana Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed results investors should review
- Earnings disclosure may affect valuation, expectations, and near-term trading in ASTH shares
Item 7.01 · Regulation FD Disclosure
- Conference call and webcast scheduled for August 6, 2026 at 2:30 p.m. Pacific Time
- Discussion covers financial results for the three and six months ended June 30, 2026
- Earnings presentation available through Astrana Health’s investor relations page, providing supplemental results context
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $972.5M, up 49%; net income attributable to Astrana $19.7M, up 109%
- Adjusted EBITDA $68.9M, up 43%; adjusted diluted EPS $0.80, up 45%, with 7% adjusted EBITDA margin
- Six-month operating cash flow $100.8M and free cash flow $92.9M, supporting investment and deleveraging capacity
- 2026 adjusted EBITDA guidance raised to $255M-$280M; revenue guidance reaffirmed at $3.8B-$4.1B
- Texas agreement adds approximately 3,000 Medicare Advantage professional-risk lives; affiliated ACOs generated $120.4M gross shared savings
Item EX-99.2 · Exhibit EX-99.2
- Q2 revenue $972.5M, up 49% year over year, with Care Partners contributing $932.8M
- Adjusted EBITDA $68.9M, up 43%, while adjusted EPS rose to $0.80 from $0.55
- FY2026 adjusted EBITDA guidance raised to $255M-$280M, signaling confidence in broad-based operating outperformance
- FY2026 revenue guidance remains $3.8B-$4.1B, while free cash flow guidance remains $105M-$132.5M
- Full-risk arrangements generated 81% of Q2 capitation revenue, supporting stronger alignment but increasing medical-cost exposure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Astrana Health, Inc. 8-K filings
Get the next ASTH 8-K as it lands
Follow ASTH for push alerts, or ask the research agent what this filing means.